Le Lézard
Classified in: Health, Business
Subject: ERN

Dialogue Health Technologies Reports Second Quarter 2023 Results


Dialogue's core digital services continued to drive growth with more than $6.7 million in net new ARR, while the adjusted EBITDA loss narrowed for a sixth consecutive quarter to less than $1 million

MONTREAL, Aug. 14, 2023 /CNW/ - Dialogue Health Technologies Inc. (TSX: CARE) ("Dialogue" or the "Company"), Canada's premier health and wellness virtual healthcare platform, announced today its financial and operational results for the three and six months ended June 30, 2023. Financial references are in Canadian dollars unless otherwise indicated.

"We delivered another strong performance during the second quarter and are executing well on our plan to drive profitable growth in the near future. We are well positioned to continue winning market share across our services, signing more than $6.7 million in net new ARR in our core digital business, including several large enterprise customers," said Cherif Habib, Chief Executive Officer of Dialogue. "Importantly, we concluded a notable licensing agreement with Sun Life in the United States, providing us with new growth opportunities and immediate scale in the world's largest addressable health and wellness market. Furthermore, we are excited about the prospects of joining forces with Sun Life, a company with whom we share a common purpose of helping people live healthier lives, and expect to drive continued innovation as we combine the strength of both organizations."

Navaid Mansuri, Chief Financial Officer, added: "We have continued to mature as an organization, transitioning from a growth-at-all-cost mindset to one that focuses on building a sustainable business for long-term success. We realized further efficiencies in our member-facing operations and reduced our operating expenses to 63% of revenue compared to nearly 76% at this time two years ago. As a result, we expanded our gross margin once again and saw a sixth consecutive quarterly improvement in adjusted EBITDA. We are well within reach of delivering our first quarter of breakeven EBITDA by the end of 2023. Getting there has been a key objective for our team and will provide Dialogue with valuable flexibility to keep innovating and to support our growth plans."

Q2 2023 Financial Highlights
(All capitalized terms not defined herein, shall have the meaning and usefulness ascribed to them in the Management's Discussion and Analysis ("MD&A") for the three and six months ended June 30, 2023. Comparison periods in each case are the three and six months ended June 30, 2022, unless otherwise stated.)

Results presented below for the comparable period in 2022 reflect continuing operations only and exclude the Occupational Health and Safety ("OHS") segment in Germany which was divested on December 31, 2022.

____________________________

1  Adjusted EBITDA is a Non-IFRS financial measure. Refer to the reconciliation contained in the Non-IFRS Financial Measures section, beginning on page 3 of this earnings release.


Q2 2023 Key Business Developments and Subsequent Events

Changes to the Board of Directors

Melissa Kennedy, Executive Vice-President, Chief Legal Officer & Public Policy Officer at Sun Life, stepped down from Dialogue's board of directors. The Company does not intend to fill the vacancy left by Ms. Kennedy's departure.

"It was a pleasure serving on Dialogue's board to further their mission of helping Canadians improve their health and well-being." said Ms. Kennedy. "The Company's recent announcement regarding the proposed acquisition of Dialogue by Sun Life is an important milestone and an exciting opportunity for both organizations. In light of the upcoming transaction, it was an appropriate time for me to step down from the board. Thank you to our Chair, fellow board members and management team."

Notice of Conference Call

As a result of the announcement on July 26, 2023, that Dialogue has entered into a definitive agreement to be acquired by Sun Life, the Company will not host a conference call with analysts.

Non-IFRS ("International Financial Reporting Standards") Financial Measures

This press release makes reference to certain non-IFRS measures, such as "EBIT" (which stands for net profit or loss before net profit or loss from discontinued operations, net financing (income) expenses and income taxes), "EBITDA" (which stands for net profit or loss before net loss from discontinued operations, net financing (income) expenses, income taxes, depreciation of property and equipment, amortization of intangible assets and amortization of right-of-use assets) and "Adjusted EBITDA" (which stands for net profit or loss before net loss from discontinued operations, net financing (income) expenses, income taxes, depreciation of property and equipment, amortization of intangible assets, amortization of right-of-use assets, disposal costs, acquisition costs, restructuring costs, transaction costs, share-based payments expense, change in contingent consideration, asset write-off and impairment and foreign exchange gain or loss). This earnings release also makes reference to Annual Recurring and Reocurring Revenue ("ARR"), Net Retention Rate ("NRR"), Member-Service Units ("MSUs"), Attach Rate and Members, which are key performance indicators. The key performance indicators used by the Company may be calculated in a manner different than similar key performance indicators used by other companies. These measures and key performance indicators are not recognized under IFRS and do not have a standardized meaning prescribed by IFRS and are therefore unlikely to be comparable to similar measures presented by other companies. Rather, these measures are provided as additional information to complement those IFRS measures by providing further understanding of our results of operations from management's perspective. Accordingly, these measures should not be considered in isolation nor as a substitute for analysis of our financial information as reported under IFRS. We also believe that other users, such as securities analysts, investors and other interested parties, frequently use non-IFRS measures, particularly in the evaluation of issuers.

Management also uses non-IFRS measures in order to facilitate operating performance comparisons from period to period, to prepare annual operating budgets and forecasts and to determine components of management compensation. Where applicable, we provide a clear quantitative reconciliation from the non-IFRS financial measures to the most directly comparable measure calculated in accordance with IFRS.

The following table reconciles net loss to Adjusted EBITDA loss for the three and six months ended June 30, 2023 and 2022:

DIALOGUE HEALTH TECHNOLOGIES INC.
ADJUSTED EBITDA
FOR THE THREE AND SIX MONTHS ENDED JUNE 30, 2023 and 2022

(in thousands of CAD)


Three months ended

June 30,


Six months ended

June 30,



2023


2022


2023


2022



$


$


$


$










Net loss


(5,757)


(8,387)


(8,412)


(15,454)

Net loss from discontinued operations


?


1,648


?


2,037

Net financing income


(518)


(169)


(1,020)


(194)

Current income tax expense


17


25


23


48

Deferred income tax expense (recovery)


920


(165)


920


(250)

EBIT


(5,338)


(7,048)


(8,489)


(13,813)

Depreciation of property and equipment


186


244


344


381

Amortization of intangible assets


491


472


979


841

Amortization of right-of-use assets


107


160


214


267

EBITDA


(4,554)


(6,172)


(6,952)


(12,324)

Share-based payments expense


1,231


954


2,091


1,522

Acquisition costs


?


541


?


634

Change in contingent consideration


201


43


(245)


134

Restructuring costs


260


15


356


15

Disposal costs


?


?


4


?

Transaction costs


1,989


?


2,112


?

Foreign exchange loss (gain)


21


165


(61)


165

Adjusted EBITDA


(852)


(4,454)


(2,695)


(9,854)


About Dialogue

Incorporated in 2016, Dialogue is Canada's premier virtual healthcare and wellness platform, providing affordable, on-demand access to quality care. Through our team of health professionals, we serve employers and organizations who have an interest in the health and well-being of their employees, members and their families. Our Integrated Health Platformtm is a one-stop healthcare hub that centralizes all of our programs in a single, user-friendly application, providing access to services 24 hours per day, 365 days per year from the convenience of a smartphone, computer or tablet. Dialogue is the first virtual care provider to receive the Accreditation Canada Primer award, a third-party validation of safety and high-level quality of care.

Forward-Looking Information

This release includes "forward-looking information" and "forward-looking statements" (collectively, "forward-looking statements") within the meaning of applicable securities laws. Forward-looking information may relate to our financial outlook (including revenues and Adjusted EBITDA), and anticipated events or results and may include information regarding our financial position, business strategy, growth strategies, addressable markets, budgets, operations, financial results, taxes, dividend policy, plans and objectives.

In some cases, but not necessarily in all cases, forward-looking statements can be identified by the use of forward-looking terminology such as "plans" "targets", "expects" or "does not expect", "is expected", "an opportunity exists", "is positioned", "estimates", "intends", "assumes", "anticipates" or "does not anticipate" or "believes", or variations of such words and phrases or state that certain actions, events or results "may", "could", "would", "might", "will" or "will be taken", "occur" or "be achieved". In addition, any statements that refer to expectations, projections or other characterizations of future events or circumstances contain forward-looking statements. Forward-looking statements are not historical facts, nor guarantees or assurances of future performance but instead represent management's current beliefs, expectations, estimates and projections regarding future events and operating performance.

Forward-looking statements are necessarily based on a number of opinions, assumptions and estimates that, while considered reasonable by Dialogue as of the date of this release, are subject to inherent uncertainties, risks and changes in circumstances that may differ materially from those contemplated by the forward-looking statements. Important factors that could cause actual results to differ, possibly materially, from those indicated by the forward-looking statements include, but are not limited to, the risk factors identified under "Risk Factors" in the Company's latest annual information form, and in other periodic filings that the Company has made and may make in the future with the securities commissions or similar regulatory authorities in Canada, all of which are available under the Company's SEDAR+ profile at www.sedarplus.ca. These factors are not intended to represent a complete list of the factors that could affect Dialogue. However, such risk factors should be considered carefully. There can be no assurance that such estimates and assumptions will prove to be correct. You should not place undue reliance on forward-looking statements, which speak only as of the date of this release. Dialogue undertakes no obligation to publicly update any forward-looking statement, except as required by applicable securities laws.

Although we have attempted to identify important risk factors that could cause actual results to differ materially from those contained in forward-looking information, there may be other risk factors not currently known to us or that we currently believe are not material that could also cause actual results or future events to differ materially from those expressed in such forward-looking information. There can be no assurance that such information will prove to be accurate, as actual results and future events could differ materially from those anticipated in such information. Accordingly, you should not place undue reliance on forward-looking information. The forward-looking information represents our expectations as of the date of this earnings release (or as the date it is otherwise stated to be made) and is subject to change after such date. However, we disclaim any intention or obligation or undertaking to update or revise any forward-looking information whether as a result of new information, future events or otherwise, except as required under applicable Canadian securities laws. All of the forward-looking information contained in this earnings release is expressly qualified by the foregoing cautionary statements.

DIALOGUE HEALTH TECHNOLOGIES INC.

INTERIM CONDENSED CONSOLIDATED STATEMENT OF NET LOSS
FOR THE THREE AND SIX MONTHS ENDED JUNE 30, 2023 AND 2022

 

(in thousands of CAD except share and per share data)

Three months ended

June 30,


Six months ended

June 30,


2023


2022


2023


2022


$


$


$


$

Continuing operations








Revenue

25,539


21,791


50,071


41,328

Cost of services

10,294


11,172


20,750


22,696

Gross profit

15,245


10,619


29,321


18,632









Operating expenses








General and administrative

11,630


11,228


20,433


19,400

Sales and marketing

4,064


2,960


8,470


6,323

Product and development

3,658


2,525


6,816


5,200

Share-based payments expense

1,231


954


2,091


1,522


20,583


17,667


37,810


32,445









Operating loss from continuing operations

(5,338)


(7,048)


(8,489)


(13,813)









Other expenses








Net financing income

(518)


(169)


(1,020)


(194)


(518)


(169)


(1,020)


(194)









Net loss before income taxes from continuing operations

(4,820)


(6,879)


(7,469)


(13,619)

Current income tax expense

17


25


23


48

Deferred income tax expense (recovery)

920


(165)


920


(250)

Net loss from continuing operations

(5,757)


(6,739)


(8,412)


(13,417)

Net loss from discontinued operations

?


(1,648)


?


(2,037)

Net loss

(5,757)


(8,387)


(8,412)


(15,454)









Loss from continuing operations per share - basic and diluted

(0.09)


(0.10)


(0.13)


(0.20)

Loss from discontinued operations per share - basic and diluted

?


(0.02)


?


(0.03)

Loss per share - basic and diluted

(0.09)


(0.12)


(0.13)


(0.23)

 

DIALOGUE HEALTH TECHNOLOGIES INC.

INTERIM CONDENSED CONSOLIDATED STATEMENT OF OTHER COMPREHENSIVE LOSS
FOR THE THREE AND SIX MONTHS ENDED JUNE 30, 2023 AND 2022

 

(in thousands of CAD)

Three months ended

June 30,


Six months ended

June 30,


2023


2022


2023


2022


$


$


$


$

Net loss from continuing operations

(5,757)


(6,739)


(8,412)


(13,417)

Net loss from discontinued operations

?


(1,648)


?


(2,037)

Net loss

(5,757)


(8,387)


(8,412)


(15,454)









Other comprehensive loss from continuing operations








Items that may be reclassified subsequently to net loss from continuing operations







Foreign currency translation gain

(79)

(18)


(707)


(69)









Item that will not be reclassified subsequently to net loss from continuing operations








Changes in fair value of investments recorded at fair value through other comprehensive income

?


?


1,004


?

Comprehensive loss from continuing operations

(5,678)


(6,721)


(8,709)


(13,348)









Other comprehensive loss from discontinued operations








Foreign currency translation gain

?


(236)


?


(544)

Comprehensive loss from discontinued operations

?


(1,412)


?


(1,493)









Total comprehensive loss

(5,678)


(8,133)


(8,709)


(14,841)

 

DIALOGUE HEALTH TECHNOLOGIES INC.

INTERIM CONDENSED CONSOLIDATED STATEMENT OF FINANCIAL POSITION
AS AT JUNE 30, 2023 AND DECEMBER 31, 2022

 

(in thousands of CAD)

June 30,


December 31,


2023


2022


$


$

Assets




Current assets




Cash and cash equivalents

29,181


62,697

Short term investments

25,000


?

Trade and other receivables

19,571


17,190

Prepaid expenses

3,631


2,443


77,383


82,330





Investment

?


1,004

Property and equipment

787


936

Right-of-use assets

570


784

Intangible assets

5,358


6,237

Goodwill

24,978


24,586

Deferred income tax asset

2,642


3,511


111,718


119,388

Liabilities




Current liabilities




Trade payable and accrued liabilities

16,933


16,724

Unearned revenue

420


912

Current portion of contingent consideration payable

1,701


1,425

Current portion of long-term debt

400


400

Current portion of lease liabilities

402


404


19,856


19,865





Non-current portion of lease liabilities

109


343

Non-current portion of long-term debt

474


707

Non-current portion of contingent consideration payable

?


664

Deferred income tax liability

422


458


20,861


22,037





Shareholders' equity




Share capital

462,028


459,962

Equity reserve

6,261


6,112

Changes in fair value of investments recorded at fair value through other comprehensive income

(1,004)


?

Cumulative translation adjustment

819


112

Deficit

(377,247)


(368,835)


90,857


97,351


111,718


119,388





DIALOGUE HEALTH TECHNOLOGIES INC.

INTERIM CONDENSED CONSOLIDATED STATEMENT OF CASH FLOWS
FOR THE SIX MONTHS ENDED JUNE 30, 2023 AND 2022

 

(in thousands of CAD)

2023


2022


$


$

Operating activities




Net loss

(8,412)


(15,454)

Items not affecting cash




Increase (decrease) of contingent consideration

(245)


134

Unrealized foreign exchange gain

(61)


?

Deferred income tax expense (recovery)

920


(250)

Depreciation of property and equipment

344


404

Amortization of right-of-use assets

214


351

Net financing income

(1,020)


(194)

Amortization of intangible assets

979


906

Share-based payments

2,091


1,522


(5,190)


(12,581)

Net changes in non-cash operating working capital items




Trade and other receivables

(1,649)


(4,014)

Prepaid expenses

(1,188)


(1,990)

Trade and other payables

376


381

Unearned revenue

(492)


691


(8,143)


(17,513)

Investing activities




Purchase of property and equipment

(194)


(419)

Purchase of intangible assets

?


(1)

Short term investments

(25,000)


?

Investment

?


(1,004)

Payment of Tictrac Ltd. contingent consideration

(136)


?

Acquisition of Tictrac Ltd. net of cash acquired

?


(24,253)

Interest income received

376


222


(24,954)


(25,455)

Financing activities




Performance share units settled in cash

?


(172)

Options exercised

180


92

Repayment of long-term debt

(233)


(200)

Repayment of lease liabilities

(252)


(512)

Interest paid

(70)


(84)


(375)


(876)

Effect of foreign currency translation

(44)


613

Net decrease in cash and cash equivalents

(33,516)


(43,231)

Cash and cash equivalents, beginning of the period

62,697


104,296

Cash and cash equivalents, end of the period

29,181


61,065

 

SOURCE Dialogue Health Technologies Inc.


These press releases may also interest you

at 05:09
Medical imaging IT and cybersecurity company Sectra (STO: SECT B) is publishing its Annual Report and Sustainability Report for the 2023/2024 fiscal year today. This report also includes the Corporate Governance Report for the same period. The...

at 03:20
Calliditas Therapeutics AB (STO: CALTX) ("Calliditas") today announces that its partner Viatris Pharmaceutical Japan G.K. ("Viatris") has initiated a phase III clinical trial in Japan with Nefecon, named VR-205 in the Japanese market, in Japanese...

at 03:00
Global biotechnology leader CSL Behring today announced that two hemophilia B patients were treated with the gene therapy HEMGENIX® (etranacogene dezaparvovec) at Hemophilia Treatment Centers in France. This milestone achievement makes HEMGENIX® the...

at 02:30
SOPHiA GENETICS , a cloud-native healthcare technology company and a global leader in data-driven medicine, today announced that Dhiti Omics Technologies, a precision molecular diagnostics service provider in India, is live on the SOPHiA...

at 01:15
Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that the Phase II/III SKYSCRAPER-06 study, evaluating tiragolumab plus Tecentriq® (atezolizumab) and chemotherapy versus pembrolizumab and chemotherapy as an initial...

at 01:05
BenevolentAI ("BenevolentAI" or the "Company") (Euronext Amsterdam: BAI), a leader in applying advanced AI to accelerate biopharma drug discovery, announces the appointment of Deutsche Numis as the Company's Financial and Capital Markets Adviser,...



News published on and distributed by: